FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): December 3, 2024

 

bdpt_8kimg5.jpg 

 

BIOADAPTIVES, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

 

000-54949

 

46-2592228

(State or Other Jurisdiction

of Incorporation)

 

(Commission File Number)

 

(IRS Employer

Identification No.) 

 

2620 Regatta Drive, Suite 102

Las Vegas, Nevada 89128

(Address of Principal Executive Office) (Zip Code)

 

(702) 659-8829

Registrant's telephone number, including area code:  

 

N/A

(former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 7.01 Regulation FD Disclosure

 

The Company issued press release on December 3, 2024, announcing the Board of Directors approval of a dividend to all common stock shareholders. The dividend is one for one with the record date projected to be in the second week of January 2025 with a payment date to be 15 days after the record date.

 

Copies of these press releases are furnished as Exhibits 99.1 to this Current Report on Form 8-K.

 

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise be subject to the liabilities of that section, nor is it incorporated by reference into any filing of the Company, under the Securities Act of 1933, or the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit Number

 

Exhibit Description

99.1

 

Press Release (12/2/24)

 

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

BioAdaptives, Inc.

 

 

 

 

 

December 5, 2024  

 

/s/ James E Keener

 

 

 

James E Keener CEO

 

 

 

3

 

nullv3.24.3
Cover
Dec. 03, 2024
Cover [Abstract]  
Entity Registrant Name BIOADAPTIVES, INC.
Entity Central Index Key 0001575142
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Dec. 03, 2024
Entity File Number 000-54949
Entity Incorporation State Country Code DE
Entity Tax Identification Number 46-2592228
Entity Address Address Line 1 2620 Regatta Drive
Entity Address Address Line 2 Suite 102
Entity Address City Or Town Las Vegas
Entity Address State Or Province NV
Entity Address Postal Zip Code 89128
City Area Code 702
Local Phone Number 659-8829
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Bioadaptives (PK) (USOTC:BDPTD)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more Bioadaptives (PK) Charts.
Bioadaptives (PK) (USOTC:BDPTD)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more Bioadaptives (PK) Charts.